No Data
No Data
Noxopharm Joins Alliance for MRNA Medicines; Shares Up Nearly 7%
Noxopharm (ASX:NOX) has joined the Alliance for mRNA Medicines as part of efforts to connect with industry leaders and promote its Sofra technology platform, according to a Tuesday filing with the Aus
Noxopharm and UniSA Receive Tour De Cure Grant for Brain Cancer Research | ASX:NOX, OTC:NOXOF
Noxopharm Receives AU$100,000 to Progress Brain Cancer Drug
Noxopharm (ASX:NOX) and the University of South Australia have received AU$100,000 from the Tour de Cure charity to progress preclinical work on a novel brain cancer drug, according to a Thursday Aust
Noxopharm Narrows Fiscal H1 Net Loss Despite Lower R&D Tax Incentive
Noxopharm (ASX:NOX) narrowed its net loss in the fiscal first half ended Dec. 31, 2023, by 54% to AU$2.5 million from AU$5.4 million in the same period a year prior. Loss per share contracted to AU$0.
Noxopharm Extends Strategic Partnership With Hudson Institute of Medical Research
Biotech company Noxopharm (ASX:NOX) renewed its strategic partnership with the Hudson Institute of Medical Research in Melbourne for a further 12-month period. The partnership and in-licensed technolo
Noxopharm Receives AU$6.1 Million R&D Tax Rebate; Shares Up 8%
Noxopharm (ASX:NOX) received a AU$6.1 million research and development tax rebate for fiscal 2023. The tax refund will help support the biotechnology company's Chroma and Sofra research and developmen
No Data